Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature
Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity. We present three new cases and a review of the literature. If PLB is suspected radiologically, the diagnosis must be confirmed by open biopsy. Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of...
Gespeichert in:
Veröffentlicht in: | Annals of hematology 2003-07, Vol.82 (7), p.440-443 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 443 |
---|---|
container_issue | 7 |
container_start_page | 440 |
container_title | Annals of hematology |
container_volume | 82 |
creator | MISGELD, E WEHMEIER, A KRÖMEKE, O GATTERMANN, N |
description | Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity. We present three new cases and a review of the literature. If PLB is suspected radiologically, the diagnosis must be confirmed by open biopsy. Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of the follicular center type. The extent of local disease manifestation, additional skeletal involvement, and the presence or absence of lymphadenopathy is assessed by radiological examination. Localized stages of the disease require involved-field radiotherapy (45-50 Gy) to the entire bone that is affected. Regional lymphatics must also be irradiated. Radiotherapy may be required immediately to prevent pathological fractures. In the few cases of more widespread skeletal or extraskeletal involvement, radiotherapy of the major site of manifestation may be followed by a "watch-and-wait" strategy until progression of the disease becomes apparent. In cases of intermediate or high-grade lymphoma of bone, combined radiochemotherapy is the treatment of choice for all stages. Six to eight cycles of chemotherapy (usually the CHOP regimen) are recommended for remission induction. This is followed by involved-field radiotherapy with 45-50 Gy. High-dose chemotherapy with autologous stem cell support is an option if there is no satisfactory response to conventional chemotherapy, or if early relapse occurs. |
doi_str_mv | 10.1007/s00277-003-0674-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73451373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2085858401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-aae9c0d5a9c6e345b0ed869fd44de91a24eda3f73945cb334e6a2112ca0c8c613</originalsourceid><addsrcrecordid>eNpdkE1rFEEURQtRzCT6A9xIIRhXpa--u7KToEYI6ELBXfGm-rXTsbtrrOpW8u_tYQYCvs3dnHt5HMZeSHgrAfy7CqC8FwBagPNG2EdsI41WAmxjHrMNBB2EXe-Mndd6ByBVY9RTdiaVd9JZ2LAfX0s_YrnnU57ETW5__uqnN5UP9-N-l0fkuePbPNEVn3eFiCesVDlOLUded7nMvNCfnv4euHlHfOhnKjgvhZ6xJx0OlZ6f8oJ9__jh2_WNuP3y6fP1-1uRjIJZIFJI0FoMyZE2dgvUNi50rTEtBYnKUIu68zoYm7ZaG3KopFQJITXJSX3BLo-7-5J_L1TnOPY10TDgRHmp0a-jUnu9gq_-A-_yUqb1t-ikAeWs8iskj1AqudZCXdwf_UQJ8eA8Hp3H1Xk8OI927bw8DS_bkdqHxknyCrw-AVgTDl3BKfX1gTPBOtME_Q_66Yj1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>614026527</pqid></control><display><type>article</type><title>Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>MISGELD, E ; WEHMEIER, A ; KRÖMEKE, O ; GATTERMANN, N</creator><creatorcontrib>MISGELD, E ; WEHMEIER, A ; KRÖMEKE, O ; GATTERMANN, N</creatorcontrib><description>Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity. We present three new cases and a review of the literature. If PLB is suspected radiologically, the diagnosis must be confirmed by open biopsy. Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of the follicular center type. The extent of local disease manifestation, additional skeletal involvement, and the presence or absence of lymphadenopathy is assessed by radiological examination. Localized stages of the disease require involved-field radiotherapy (45-50 Gy) to the entire bone that is affected. Regional lymphatics must also be irradiated. Radiotherapy may be required immediately to prevent pathological fractures. In the few cases of more widespread skeletal or extraskeletal involvement, radiotherapy of the major site of manifestation may be followed by a "watch-and-wait" strategy until progression of the disease becomes apparent. In cases of intermediate or high-grade lymphoma of bone, combined radiochemotherapy is the treatment of choice for all stages. Six to eight cycles of chemotherapy (usually the CHOP regimen) are recommended for remission induction. This is followed by involved-field radiotherapy with 45-50 Gy. High-dose chemotherapy with autologous stem cell support is an option if there is no satisfactory response to conventional chemotherapy, or if early relapse occurs.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-003-0674-5</identifier><identifier>PMID: 12761650</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Biological and medical sciences ; Bone Neoplasms - diagnosis ; Bone Neoplasms - therapy ; Cancer ; Chemotherapy ; Combined Modality Therapy ; Diagnostic Imaging ; Female ; Hematologic and hematopoietic diseases ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma ; Lymphoma, Non-Hodgkin - diagnosis ; Lymphoma, Non-Hodgkin - therapy ; Male ; Medical sciences ; Middle Aged ; Radiation therapy ; Remission Induction - methods</subject><ispartof>Annals of hematology, 2003-07, Vol.82 (7), p.440-443</ispartof><rights>2003 INIST-CNRS</rights><rights>Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-aae9c0d5a9c6e345b0ed869fd44de91a24eda3f73945cb334e6a2112ca0c8c613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14956489$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12761650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MISGELD, E</creatorcontrib><creatorcontrib>WEHMEIER, A</creatorcontrib><creatorcontrib>KRÖMEKE, O</creatorcontrib><creatorcontrib>GATTERMANN, N</creatorcontrib><title>Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity. We present three new cases and a review of the literature. If PLB is suspected radiologically, the diagnosis must be confirmed by open biopsy. Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of the follicular center type. The extent of local disease manifestation, additional skeletal involvement, and the presence or absence of lymphadenopathy is assessed by radiological examination. Localized stages of the disease require involved-field radiotherapy (45-50 Gy) to the entire bone that is affected. Regional lymphatics must also be irradiated. Radiotherapy may be required immediately to prevent pathological fractures. In the few cases of more widespread skeletal or extraskeletal involvement, radiotherapy of the major site of manifestation may be followed by a "watch-and-wait" strategy until progression of the disease becomes apparent. In cases of intermediate or high-grade lymphoma of bone, combined radiochemotherapy is the treatment of choice for all stages. Six to eight cycles of chemotherapy (usually the CHOP regimen) are recommended for remission induction. This is followed by involved-field radiotherapy with 45-50 Gy. High-dose chemotherapy with autologous stem cell support is an option if there is no satisfactory response to conventional chemotherapy, or if early relapse occurs.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - diagnosis</subject><subject>Bone Neoplasms - therapy</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Diagnostic Imaging</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - diagnosis</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Radiation therapy</subject><subject>Remission Induction - methods</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1rFEEURQtRzCT6A9xIIRhXpa--u7KToEYI6ELBXfGm-rXTsbtrrOpW8u_tYQYCvs3dnHt5HMZeSHgrAfy7CqC8FwBagPNG2EdsI41WAmxjHrMNBB2EXe-Mndd6ByBVY9RTdiaVd9JZ2LAfX0s_YrnnU57ETW5__uqnN5UP9-N-l0fkuePbPNEVn3eFiCesVDlOLUded7nMvNCfnv4euHlHfOhnKjgvhZ6xJx0OlZ6f8oJ9__jh2_WNuP3y6fP1-1uRjIJZIFJI0FoMyZE2dgvUNi50rTEtBYnKUIu68zoYm7ZaG3KopFQJITXJSX3BLo-7-5J_L1TnOPY10TDgRHmp0a-jUnu9gq_-A-_yUqb1t-ikAeWs8iskj1AqudZCXdwf_UQJ8eA8Hp3H1Xk8OI927bw8DS_bkdqHxknyCrw-AVgTDl3BKfX1gTPBOtME_Q_66Yj1</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>MISGELD, E</creator><creator>WEHMEIER, A</creator><creator>KRÖMEKE, O</creator><creator>GATTERMANN, N</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030701</creationdate><title>Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature</title><author>MISGELD, E ; WEHMEIER, A ; KRÖMEKE, O ; GATTERMANN, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-aae9c0d5a9c6e345b0ed869fd44de91a24eda3f73945cb334e6a2112ca0c8c613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - diagnosis</topic><topic>Bone Neoplasms - therapy</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Diagnostic Imaging</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - diagnosis</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Radiation therapy</topic><topic>Remission Induction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MISGELD, E</creatorcontrib><creatorcontrib>WEHMEIER, A</creatorcontrib><creatorcontrib>KRÖMEKE, O</creatorcontrib><creatorcontrib>GATTERMANN, N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MISGELD, E</au><au>WEHMEIER, A</au><au>KRÖMEKE, O</au><au>GATTERMANN, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>82</volume><issue>7</issue><spage>440</spage><epage>443</epage><pages>440-443</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity. We present three new cases and a review of the literature. If PLB is suspected radiologically, the diagnosis must be confirmed by open biopsy. Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of the follicular center type. The extent of local disease manifestation, additional skeletal involvement, and the presence or absence of lymphadenopathy is assessed by radiological examination. Localized stages of the disease require involved-field radiotherapy (45-50 Gy) to the entire bone that is affected. Regional lymphatics must also be irradiated. Radiotherapy may be required immediately to prevent pathological fractures. In the few cases of more widespread skeletal or extraskeletal involvement, radiotherapy of the major site of manifestation may be followed by a "watch-and-wait" strategy until progression of the disease becomes apparent. In cases of intermediate or high-grade lymphoma of bone, combined radiochemotherapy is the treatment of choice for all stages. Six to eight cycles of chemotherapy (usually the CHOP regimen) are recommended for remission induction. This is followed by involved-field radiotherapy with 45-50 Gy. High-dose chemotherapy with autologous stem cell support is an option if there is no satisfactory response to conventional chemotherapy, or if early relapse occurs.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>12761650</pmid><doi>10.1007/s00277-003-0674-5</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-5555 |
ispartof | Annals of hematology, 2003-07, Vol.82 (7), p.440-443 |
issn | 0939-5555 1432-0584 |
language | eng |
recordid | cdi_proquest_miscellaneous_73451373 |
source | MEDLINE; SpringerLink Journals |
subjects | Adult Biological and medical sciences Bone Neoplasms - diagnosis Bone Neoplasms - therapy Cancer Chemotherapy Combined Modality Therapy Diagnostic Imaging Female Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma Lymphoma, Non-Hodgkin - diagnosis Lymphoma, Non-Hodgkin - therapy Male Medical sciences Middle Aged Radiation therapy Remission Induction - methods |
title | Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T04%3A57%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20non-Hodgkin's%20lymphoma%20of%20bone:%20three%20cases%20and%20a%20short%20review%20of%20the%20literature&rft.jtitle=Annals%20of%20hematology&rft.au=MISGELD,%20E&rft.date=2003-07-01&rft.volume=82&rft.issue=7&rft.spage=440&rft.epage=443&rft.pages=440-443&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-003-0674-5&rft_dat=%3Cproquest_cross%3E2085858401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=614026527&rft_id=info:pmid/12761650&rfr_iscdi=true |